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Targeted therapySupplement Introduction
The introduction of targeted therapy with monoclonal anti-
bodies (mAbs) has improved efficacy of treatment and
prognosis for cancer patients with solid tumors or hemato-
logic malignancies in the past decade 1. Older patients with
cancer also derive benefit from biologic therapies, although
they may require more careful assessment and treatment
selection compared with younger patients, depending on
overall performance status and potential comorbidities 2–4.Lichtman, MD, FACP and
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In this supplement, we present an overview of the
development, approval requirements, and characteristics of
biosimilar mAbs that may help practicing oncologists and
other healthcare providers to acquire familiarity with this
new group of therapeutic biologic agents. Further, in the
second section, we review and discuss some of the challenges
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consensus is emerging on the need to tailor treatment for
older patients; chronologic age per se should not dictate the
course of action. Optimization of patient assessments and
current treatment algorithms and access to efficacious and
safe therapies as well as implementation of well-designed
clinical trials may help provide effective treatment options for
older patients with cancer 5–7.
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Introduction
Biologic drugs encompass a wide range of products such as
hematopoietic growth factors (e.g. erythropoietin, filgrastim),
recombinant hormones (e.g. growth hormone), and targeted
monoclonal antibodies (mAbs) (e.g. anti-HER2 mAb
trastuzumab, anti-CD20 mAb rituximab, and anti-epidermal
growth factor receptor mAbs cetuximab and panitumumab) 1.
Biosimilars are biologic drugs designed to be highly similar to
the reference biologic product, also known as the originator
2–6. In contrast to generic drugs, which can be identical to their
reference product, most biosimilars are highly complex
molecules produced in vitro by recombinant DNA technology.
Further, biosimilar mAbs undergo post-translational modifi-
cations (e.g., glycosylation) and assembly in multi-chain,immunoglobulin structures 7. Minor differences may thus be
present in clinically inactive components of biosimilar prod-
ucts 6. However, by definition, a biosimilar is “a biologic
product that is highly similar to a reference biologic product,
notwithstanding minor differences in inactive components,”
and for which there are “no clinically meaningful differences
in safety, purity, or potency of the product” (H. R. 3590-686.
Title VII. Subtitle A- BPCI Act. §7002) 5, 6.
The concept of a “similar biological medicinal product”
was first introduced in the European pharmaceutical legisla-
tion in 2003 and the legal basis for the biosimilar approval
pathway was adopted in 2004, coming into effect in 2005 1.
Regulatory guidance documents for the definition, approval,
and the use of biosimilars were initially released in Europe by
the European Medicines Agency (EMA) in 2005 with later
updates 2,3. In 2009, the World Health Organization (WHO)
published its “Guidelines for the evaluation of similar
biotherapeutic products (SBPs)” 4. In 2010, the Patient Protec-
tion and Affordable Care Act was signed into law and created
a pathway for the approval of biosimilars in the United States
5. Guidance documents were subsequently released in the
United States by the Food and Drug Administration (FDA) in
2012 and 2015 6, 7. These regulatory approval pathways outline
the biosimilar paradigm, which requires a sponsor to demon-
strate biosimilarity between the proposed product and a
reference product, and to demonstrate that “there are no
clinically meaningful differences between the biologic prod-
uct and the reference product” 5, 6, 8.
In this review we outline current requirements for approv-
al of biosimilars, discuss the rationale for the development of
biosimilar mAbs in oncology, and address their potential
impact in the management of older patients with cancer.
Evaluation and Approval Requirements for Biosimilars
According to current regulatory guidance from the EMA and the
FDA, a stepwise process involving pre-clinical and clinical
evaluations is required to determine biosimilarity to a refer-
ence product, including demonstration of comparable safety
and efficacy (Fig. 1) 2, 6. Pre-clinical, comparative studies of
potential biosimilars rely on physicochemical characterization
and on in vitro bioassays for the evaluation of structural and
functional properties (e.g. peptide mapping, in vitro cytotoxic-
ity assays). In vivo animal and human studies are conducted to
evaluate pharmacokinetic (PK) characteristics, safety, immu-
nogenicity, and pharmacodynamic (PD) effects of biosimilars.
Comparative PK and PD analyses may be performed in the
same study, allowing determination of biosimilarity in PK
profiles and in vivo effects on preselected biomarkers or target
cells (e.g. patterns of B cell depletion by CD20-targeted mAbs).
PD studies should include determination of the relevance of
available PD biomarkers for the stated mechanism of action,
time of the PD marker onset relative to dosing, and sensitivity
of the PD marker to differences between a biosimilar and its
reference product as well as correlations between changes in
PD markers and clinical outcomes 6, 8.
Potential biosimilars are further evaluated in head-to-head
comparative clinical trials designed to assess biosimilarity
between a biologic drug and its reference product in patient
populations sensitive to potential differences in clinical
Pre-clinical, in vitro 
comparative studies
Analytical studies (eg, peptide mapping)
Bioassays (eg, in vitro cytotoxicity)
In vivo 
comparative studies
(animal and human studies)
Pharmacokinetic profile
Pharmacodynamic effects
Safety
Immunogenicity
Safety
Efficacy
Immunogenicity
Pharmacokinetics
Clinical trials
vs. reference product in 
sensitive patient populations
Fig. 1 – Stepwise evaluation of biosimilars [2, 6, 8].
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efficacy 6. Clinical trial endpoints should be selected to
maximize detection of potential differences between the
biosimilar and the reference product rather than to redefine
overall clinical benefit, which was already established in
clinical studies conducted with the reference biologic 2,6.
Accordingly, sample size and duration of comparative studies
should allow assessment of any potential difference, includ-
ing any newly emerging safety signals 6. Endpoints for clinical
immunogenicity studies should include measurements of
immune response to the biosimilar and to the reference
product, such as specific antibody responses (e.g., titer, time
of development, persistence, disappearance, and neutralizing
activity) and cytokine levels 6. In some cases, appropriately
selected pharmacodynamic endpoints known to be correlated
with clinical outcomes in the study populations may allow for
more accurate comparative studies of biosimilars and their
reference products than clinical endpoints. Concomitant
evaluation of multiple pharmacodynamics endpoints may
further enhance the sensitivity of the comparative clinical
studies undertaken for biosimilars 6. Introduction of novel,
exploratory endpoints tailored to specific biologic drugs and
clinical settings may also be considered in building the body
of evidence required to establish biosimilarity in pivotal
clinical trials 6,9,10.
The FDA has recently approved the first biologic product
through the biosimilar regulatory pathway, Zarxio™ (Sandoz/
Novartis, Basel, Switzerland), which is a biosimilar version of
the hematopoietic growth factor filgrastim. In this case,
primary endpoints in the pivotal study EP06-109 conducted
in 28 healthy volunteers were biosimilarity in pharmacoki-
netics and pharmacodynamics (absolute neutrophil count).
The secondary endpoints of this study included safety,
immunogenicity, and local tolerance. Further, primary end-
point of the pivotal clinical study EP06-302 conducted in 218
patients with breast cancer treated with myelosuppressive
chemotherapy was non-inferiority in mean duration of severe
neutropenia in cycle 1. Mean patient age in this trial was
49 years (range, 23–76 years). Overall, only 30 (approximately
9%) of the 334 female breast cancer patients included in thebiosimilar filgrastim pivotal studies EP06-301 and EP06-302
were >65 years of age 11. Furthermore, the FDA has also
recently accepted applications for other biosimilars.
Rationale for the Development of Biosimilars in Oncology
MAbs directed to key targets expressed by cancer cells, such
as trastuzumab, cetuximab, panitumumab, bevacizumab,
rituximab, and ofatumumab have been approved to treat
patients with HER-2+ breast cancer, head and neck cancer,
non-squamous non-small-cell lung cancer, colorectal cancer,
or hematologic malignancies (e.g. lymphoma and chronic
lymphocytic leukemia), respectively, and have led to more
effective standard-of-care treatments for these patient popu-
lations 1. However, future availability of essential therapeutic
agents in oncology may be compromised by the loss of patent
protection and market exclusivity projected to occur within
the next 3–4 years for a number of these mAbs 1. There have
been a number of shortages reported globally in the past few
years for non-branded, generic but essential oncologic drugs,
including 5-fluorouracil, bleomycin, cytarabine, doxorubicin,
and fludarabine as well as antibiotics, analgesics, and
parenteral nutrition products, which have affected availability
of treatment options, patient safety, and overall healthcare
costs 12.
Biosimilars need be differentiated from “intended copies”
or “non-comparable versions” of biologic drugs, which are
products now being marketed in some countries in Central/
South America and in Asia 13,14. These products may not have
been developed according to strict WHO standards and thus
may not have been developed through the stepwise, compar-
ative, pre-clinical and clinical studies required to demonstrate
biosimilarity to the reference product 4,15. In contrast,
biosimilars approved by health authorities (e.g. EMA or the
FDA) and produced according to current industry standards 16
are expected to be high-quality biologics that may sustain and
increase access to biologic therapies for patients with cancer.
An Office of Pharmaceutical Quality has been recently opened
by the FDA within the Center for Drug Evaluation and
Research, which is expected to establish benchmarks for
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Manufacturing Practices (GMPs) intended to ensure effective
oversight of manufacturing operations throughout the life
cycle of a pharmaceutical product. In the case of drugs
approved for use by the FDA but not produced in compliance
with current GMPs, the severity of the violations identified
generally determines the nature and extent of the FDA
regulatory actions. In rare cases, the FDA may ask a company
to stop distribution or manufacturing of a pharmaceutical
product if it is found in serious violation because it does not
meet its labeled specifications and may endanger safety and
effective treatment of patients 16.
Further, to provide state-of-the-art information on
biosimilar development and approval, the FDA has initiated
a dedicated source called the Purple Book or “Lists of Licensed
Biological Products with Reference Product Exclusivity and
Biosimilarity or Interchangeability Evaluations,” which is
easily accessible through its website 17. Such lists are updated
periodically and will include biosimilars upon approval.
Further sources of information on biologics and biosimilars
are provided here by the FDA both for healthcare providers
and consumers.
Emerging Biosimilar mAbs and Potential Impact in Cancer Care
In response to the challenges that may affect availability of
key biologics frequently used for the treatment of patients
with cancer, a number of biosimilarmAbs are being developed
according to current FDA/EMA/WHO regulatory guidance
and expectations and GMP standards by well-established
manufacturers, including biosimilars to trastuzumab, rituxi-
mab, and cetuximab 1, 15, 16. For the biosimilars approved
through the EMA or FDA regulatory pathways, post-marketing
implementation of appropriate pharmacovigilance programs
and reporting of adverse drug reactions by established
manufacturers will allow surveillance of their use in daily
clinical practice 18–20. This is especially important for older
patients because comorbid conditions and a reduction in
organ reserves can alter drug tolerance. In addition, recent
pharmacoeconomic analyses suggest that biosimilars may
have a substantial impact on the range of treatment options
available to clinicians, patients, and payers in many settings
14,21–24. For example, according to a recent model, cost-savings
deriving from the use of biosimilars in supportive care in
France, Germany, Italy, the United Kingdom, and Spain would
allow increased access to anticancer biologics without addi-
tional expenditures 23. A broad access to biosimilar anticancer
mAbs may further help in addressing financial issues
experienced by patients and their families or financial
toxicity, which has been defined, on a graded scale, as the
potential impact of healthcare-related costs on standard of
living, quality of life, treatment selection and adherence, and
ultimately treatment outcomes 25. In a global community
conscious of healthcare costs and driven to implement
cost-effective treatment plans with preservation of access to
high quality of care, biosimilars may be a lower cost
alternative to off-patent biologic therapies and provide
efficiencies to healthcare systems. Furthermore, achievement
of a suitable balance between a broader adoption of biosimilar
products and the concomitant development of novel,innovative products for potential inclusion in combination
regimens frequently used in oncology, may represent an
effective strategy within an evolving therapeutic landscape.
In conclusion, the introduction of high-quality biosimilars
may provide access to biologic therapies to a greater number
of patients with cancer, who are seeking safe and effective
treatment options, including older patients with cancer.
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Oncol 2014;32:3337–3338.Second Section — Evolving Cancer Treatment for
Older Patients: Biosimilars
Introduction
Cancer affects a substantial proportion of older adults, and it
represents one of the leading causes of death in this
population. Based on the demographic changes currently
occurring in developed countries, a further increase in the
number of cancer patients aged 70–75 years or more is
expected for the next decades 1–5. A number of challenges
are frequently encountered in daily clinical practice by
oncologists caring for older adults, including the presence of
comorbidities (e.g. cardiovascular disease, compromised re-
spiratory or renal function, liver abnormalities, cognitive
deficits), a reduced tolerability for treatment-related toxic-
ities, the need for multiple concomitant medications
(polypharmacy), a reduced performance status, and a com-
promised ability to perform daily basic activities as well as
limited transportation, social support, and financial resources
6. These epidemiologic and clinical trends underscore the
growing importance of optimizing diagnosis and therapeutic
interventions in geriatric oncology to better address the needs
of older patients with cancer 2, 6.
Effective geriatric screening and assessments, appropriate
referrals, careful selection of treatment options tailored to
each patient conditions, access to standard of care and
innovative treatments as well as adequate supportive care
represent main objectives in the multidisciplinary manage-
ment of older patients with cancer 1, 2, 5, 7–9.
In this section, we outline the progressmade so far in some
key areas of geriatric oncology and discuss treatment patterns
with targeted biologic therapies and their implications for
older patients with cancer, in view of the ongoing develop-
ment and future availability of biosimilar monoclonal anti-
bodies (mAbs).
Screening and Assessment of the Geriatric Patient with Cancer
The decrease in functional reserves associated with aging, as
well as the presence of potential comorbidities and the
frequent need for polymedication, render each older patient
unique in their status, thus requiring careful screening and
assessment at an individual level if cancer is suspected or
diagnosed. Accurate assessment of a patient's performance,
medical condition, functional reserve, and goals of care is the
key to selecting appropriate treatment options, to prevent
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able patients and to avoid undertreatment of fit patients
simply based on older age 7–14.
To achieve these goals, a substantial number of screening
tools have been developed for the assessment of older
patients. Five of these tools have been specifically designed
for older patients with malignancies: Geriatric 8 (G8) tool, the
Oncogeriatric Screen (OGS), the abbreviated Comprehensive
Geriatric Assessment (aCGA), the Senior Adult Oncology
Program questionnaire (SAOP2), and Gerhematolim 10. G8
has shown value in predicting chemotherapy-associated
toxicity and overall survival (OS) in older patients with solid
tumors but not with hematologic malignancies. Conversely,
Gerhematolim has demonstrated a high sensitivity (95%) and
specificity (87%) in older patients with hematologic malig-
nancies. The aCGA tool contains 15 of the most important
items present in the full CGA and has demonstrated a
sensitivity of about 50% and specificity of 97% compared
with the CGA 10.
Polypharmacy and Clinical Pharmacology Considerations for Older
Patients With Cancer
Administration of multiple medications occurs frequently in
older patients due to the presence of comorbidities and the
need for specific treatments. Other factors contributing
to polypharmacy may derive from a lack of coordination
between specialists and primary care physicians as well
as routine continuation of prior therapies. In the oncology
setting, polymedication is often further accentuated by the
need to treat adverse drug reactions 15–24.
As the aging process and comorbidities may further
interfere with absorption, metabolism, and excretion of
drugs and their metabolites, drug administration in older
patients should be tailored to their age, goals of care, and
physical characteristics (e.g. weight and renal or liver func-
tion), carefully planned and continuously monitored to
prevent unwanted toxicities and undesired reactions 15, 18, 23.
Periodical re-evaluation of all medications taken by a
patient may also contribute to a correct long-term treatment
strategy and optimal outcomes 19. The use of a Medication
Appropriateness Index (MAI), as well as of the Beer's or the
STOPP criteria (screening tool of older persons' potentially
inappropriate prescriptions), may help in this process 15–17. In
a patient assessment it is important to collect detailed
information on the use of over-the-counter medications and
“natural products” (e.g. herbal remedies not regulated by the
health authorities), as potential pharmacologic interactions
with other medications or undesired adverse effects may be
associated with their use and thus influence treatment
decisions or overall outcomes 25,26.
Over- and undertreatment are both potential risks associ-
ated with the management of older patients. A reduction in
the functional reserves, frailty, and comorbidities may require
reductions in the dose intensity or delays in treatment to
prevent overtreatment and toxicity. Conversely, appropriate
medical treatment should not be withheld from a patient with
cancer who is fit and in good general and clinical conditions,
simply based on advanced age (e.g. 70–75 years or older) 27–31.
Biologic age trumps chronologic age 32. Although the presence ofcomorbidities and the related polypharmacy may represent a
challenge for inclusion of some older patients in clinical trials
(due to the potential introduction of hard-to-quantify variables)
and affect their eligibility for comparative studies of biologic
agents including biosimilars, careful patient screening and
selection would allow inclusion of older but fit patients.
Access to Biologic Agents and Biosimilars for Older Patients With
Cancer
Review of the demographic characteristics of patients includ-
ed in oncology clinical trials reveals that, generally, very few
older patients (aged 70–75 years or older) are enrolled in
clinical studies, as they frequently do not meet the specified
inclusion criteria, or are treated in settings that have no
access or infrastructure to support clinical trials 33–42. “Age-
ism,” which occurs when older patients are eligible for a
clinical trial but are not offered the opportunity to participate,
may also significantly contribute to low or no enrollment of
this patient population in clinical trials, as exemplified in a
case–control study conducted in the breast cancer setting 35.
Importantly, non-inclusion of older patients in cancer trials
may deprive them of early access to investigational treat-
ments with greater efficacy or better tolerability compared
with available standard treatments.
Once suitable treatment options have been identified for
each patient with cancer, individual access to treatment
becomes of key importance; however, logistic, financial,
and practical issues may build barriers to effective patient
management 43. Appropriate referrals at cancer diagnosismay
help patients and their caregivers identify clinical providers
and oncologic teams that may effectively deliver high-quality
cancer care over the course of the disease. A multidisciplinary
and inter-professional approach with integration of the care
provided by medical, surgical, and radiation oncologists and
by geriatricians and primary care physicians is also necessary
to ensure that patients are optimally treated for their cancer
and all the potential comorbidities in a synergistic continuum
of care.
The ongoing development and future approval of
biosimilar anticancer agents is expected to increase patient
access to mAbs, such as trastuzumab, rituximab, cetuximab,
and panitumumab, in addition to the hematopoietic growth
factors frequently used in supportive care 43–45. These mAbs
are currently integrated in standard-of-care regimens for
the treatment of early and advanced breast cancer (BC),
lymphoma (e.g. diffuse large-B cell lymphoma; DLBCL),
chronic lymphocytic leukemia, locally advanced head and
neck squamous cell carcinoma, and metastatic colorectal
cancer, among other malignancies. They have demonstrated
safety and efficacy in the general patient population and in
selected cohorts of older patients, mostly evaluated in
retrospective analyses or registry studies 28,43,46–51.
Results from a survey conducted among oncologists in the
United States and in other countries (i.e. Brazil, Mexico,
Russia, and Turkey) have shown that multiple barriers may
limit access to HER2-targeted treatment with trastuzumab in
the adjuvant, neoadjuvant, and metastatic BC setting 48. A
total of 7994 full-time physicians involved in patient care were
invited to participate in this survey, with an overall,
S7J O U R N A L O F G E R I A T R I C O N C O L O G Y 7 ( 2 0 1 6 ) S 1 – S 8 T H I S S U P P L E M E N T W A S F U N D E D B Y P F I Z E Rpre-specified goal of 200 responders in the United States, and
75 each in Brazil, Mexico, Russia, and Turkey (N = 500) 48.
Further analysis of these survey results revealed that ~30% of
the responders reported not being able to prescribe
trastuzumab as needed or having to delay treatment. Such
percentage rose to 60% in the United States for difficulties in
prescribing trastuzumab for patients with HER2+ metastatic
BC 48. Of note, approximately half of the responding oncolo-
gists said that they would increase the use of HER2-targeted
mAb therapy in all clinical settings for patients with HER2+ BC
with the availability of a trastuzumab biosimilar product 48.
Similarly, in the United States as well as in emerging
countries, physicians may encounter barriers in prescribing
rituximab for patients with non-Hodgkin lymphoma or
chronic lymphocytic leukemia, as reported in a recent survey,
conducted among 450 hematologists and oncologists who
completed this survey in the United States, Mexico, Turkey,
Russia, and Brazil 50. In addition, in a recent SEER-Medicare
cohort analysis of 9333 patients with DLBCL, older than
66 years of age, 49% of the patients had received rituximab
in combination with chemotherapy compared with 23% who
received only chemotherapy and 5% who received only
rituximab. However, 23% of patients did not receive any
treatment, particularly those aged 80 years or older (33%) 51.
In conclusion, the future approval and use of biosimilars in
many solid and hematologic malignancies may address the
evolving needs of patients and physicians, generate efficien-
cies for healthcare systems, and provide broader access to
standard-of-care treatment options for older patients with
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